London Biotechnology Show

Join Discovery Park as we attend the inaugural London Biotechnology Show.

The London Biotechnology Show aims to be a premier biotechnology event in the UK and the broader European region to expedite the progress of biotechnology for revolutionising medical & healthcare sectors globally.

The show will deliver an impeccable event experience for the participants to discover the latest technological advancements & ground-breaking offerings and simultaneously deliberate on the ways to widen the scope of biotechnology around the globe.

Find out more and register here.

OBN BioTrinity 2024

Join Discovery Park as we attend BioTrinity 2024. 

BioTrinity is OBN’s flagship two-day conference for the life sciences industry, designed to catalyse growth for all who attend. The delegate mix comprises early stage and emerging life sciences R&D companies, investors, big pharma, academics, charities, government, and broad range of valued service providers.

Find out more and register here.

OBN BioSeed 2024

Join Discovery Park as we attend OBN BioSeed, now in its seventh year!

BioSeed is a fast-paced, one-day pitching event where innovative early-stage life sciences companies seeking seed funding, showcase to and meet with an extensive audience of active life sciences investors.

Find our more and register here


Discovery Park Suppliers Fair

Join us for an exclusive showcase of cutting-edge solutions and services at the Discovery Park Suppliers Fair. Explore a diverse range of offerings from leading suppliers in the industry.


Why Attend?

  • Connect with Top Suppliers
  • Explore Latest Technologies
  • Network with Industry Experts
  • Discover Solutions for Your Business Needs

Don’t miss this opportunity to stay ahead in the world of innovation! Mark your calendar and be a part of the Discovery Park Suppliers Fair.


Top Suppliers attending the day:

Lab Assets Limited

Canterbury Christ Church University

Teledyne Labs


Haynes Ford Canterbury

Opentrons Labworks

Veolia Water Technologies

Agenda Life Sciences

Eurogentec Ltd

PHC Europe B.V.

Haier BiomedicalInivos UK LTD

Cool Repair Scientific UK & MTS Cryostores UK

A4P Bio

Raumedic UK Ltd

Avidity Science

Restore Harrow Green Laboratory Services

Nikon Healthcare

Carl Zeiss / Appleton Woods

CliniSciencesLS Scientific


Register here

Metabolite Identification Expert – Sandwich, Kent

York Bioanalytical Solutions is the premier, independent UK-based provider of bioanalytical, metabolism and ADME services to the world’s pharmaceutical industry. As such, we have strong ideas about the value of our staff in providing a top quality scientific service to our clients and recognise the importance of providing an environment in which our employees feel valued and can develop to the best of their abilities.

Following significant expansion of our DMPK section, we require an experienced scientist to join our friendly, professional team. The successful candidate will play a leading role in the delivery of metabolite characterisation studies in support of human or animal health drug discovery and development, at our facility at Discovery Park in Sandwich, Kent.


The ideal candidate will have:
• In-depth knowledge of metabolite characterisation strategies across drug discovery and development
• Significant expertise in the application of relevant analytical tools to metabolite characterisation studies, including HPLC, radiochemical
detection, UV and mass spectrometry (both nominal mass and high-resolution)
• Detailed understanding of metabolism and enzymology and their significance to drug discovery and drug development programs
• Ability to design and perform iterative metabolism experiments and troubleshoot analytical issues
• Ability to train others to perform all aspects of metabolite characterisation studies
• Flexibility to undertake multiple, potentially complex studies in parallel
• Aptitude for scientific publications, presentations and customer interactions
• A meticulous approach to record keeping and report preparation


Candidates will ideally be educated to degree or higher degree level in a relevant scientific subject. At least 5 years’ experience of work in a metabolite characterisation role is essential. The grading of the role is flexible dependent on experience and relevant qualifications


If you would like to work in a friendly and flexible environment and feel you have the right qualities, please send a detailed CV to:

Angus Nedderman, York Bioanalytical Solutions, Discovery Park House, Discovery Park, Ramsgate Road, Sandwich, Kent, CT13 9ND;


BugBiome wins Discovery Spark life science programme

  • BugBiome wins a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures
  • BioMavericks was awarded the wildcard prize as voted for by the audience at the GIANT Health Healthcare Investment Show on 5th December

BugBiome was announced as the winner of the Discovery Spark life science business support programme at the GIANT Health Healthcare Investment Show on 5th December. BugBiome will be awarded a business support package worth over £100,000, including one year of free lab space at Discovery Park and £50,000 investment from Discovery Park Ventures.

Eleven start-ups took part in the programme, including 3D Synthesis, Awen, Bing Bong Bio, BioMavericks, BugBiome, CardioCrown, DLOC Biosystems, Dravya Discovery, KASNMR, Rapidx Bio, and The Future Care. They participated in in-person training sessions, covering topics such as building an excellent team, understanding and conveying business metrics, and building a strong brand, as well as extensive networking and mentoring opportunities. Having refined their pitches throughout the programme, six finalists pitched to investors and other audience members as part of the GIANT Health conference.

BugBiome was chosen as the overall winner based on its promising business offering and extensive progress throughout the programme. The company is harnessing the power of the skin microbiome to repel pests, utilising natural bacteria to create effective, long-lasting repellents.

Alicia Showering, Founder and CEO at BugBiome, said: “We’re so excited to win the Discovery Spark programme following a fantastic eight weeks learning from industry leaders and our fellow start-ups. We’re passionate about stopping the spread of deadly vector-borne diseases like malaria and dengue and Discovery Spark has given us some excellent tools and connections to further progress our business and make this a reality.”

Based on the strength of the participating companies, Discovery Park decided to offer a wildcard prize in addition to the overall winner. BioMavericks was selected as the wildcard winner, following the audience vote at the GIANT Health Healthcare Investment Show. The company will be awarded six months free lab space at Discovery Park as well as business support from Barclays Eagle Labs and the programme’s partners. BioMavericks is an early-stage biotech start-up, focused on developing an in vitro diagnostic blood test for pancreatic cancer to revolutionise cancer diagnostics using AI-driven biotechnology.

Discovery Park’s Head of Innovation, Renos Savva, who led the programme, said: “We were thrilled to welcome such a promising group of start-ups to Discovery Park to share experience and ideas from specialists within the industry. We saw all of the participants develop their businesses over the course of the programme and I am excited to witness their further growth in the coming months and years. Choosing the winner was a very tough task and I would like to congratulate all the companies involved. Particular congratulations go to BugBiome and BioMavericks on their wins, and I look forward to welcoming them to Discovery Park and continuing to work with them. Many thanks to all our supporting companies, facilitators and advisors for making the programme such a success.”

Mayer Schreiber, CEO at Discovery Park, added: “The Discovery Park team prides itself on supporting the next generation of life science leaders, and our Discovery Spark programme is the embodiment of that. Working with these companies has demonstrated the wealth of innovation we have in the UK and it excites me to see how they will progress in the future. Congratulations to the winners, we look forward to welcoming you to Discovery Park soon.”

Thank you to our prize partners and facilitators including Kreston Reeves, SRG, Prismea Limited, Sciad Communications, Abel + Imray, Barclays Eagle Labs, Researcher, Janne Bate, Phillipa Clark, Michal Barski, Michael O’Neill, Michelle Yeoman ACC, David Savva, Mark Preston, Cameron Watson, Helen Banyard, James Easley.

Discovery Park Ventures expands fund to £3m to invest in more innovative science and technology start-ups

Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1m to £3m, in order to capitalise on exciting investment opportunities and support its existing portfolio. The fund’s investors have committed an additional £2m, which will also enable the fund to take larger stakes in companies that strongly align with its strategic objectives.

DPV was formed in 2022 by Discovery Park to invest in promising, fast-growing life-science companies with close links to the innovation ecosystem at Discovery Park. The first £1m tranche of DPV is now fully invested. Recent investments include Optceutics Ltd, an ophthalmology drug development company that uses its pharmacokinetic model, PK-Eye™, to accelerate the development of ocular formulations. Two others will be announced shortly. DPV is also invested in Vitarka Therapeutics, VisusNano, Booby Biome, Neobe Therapeutics, Ignota Labs and Oxford Medical Products.

The first transactions from the second tranche of the fund have been follow-on funding rounds into two existing portfolio companies, one of which is Ignota Labs (focused on preventing safety failures in drug discovery with Explainable AI). New investments are also being reviewed. Discovery Park Ventures will be presenting some of its portfolio at Giant Health’s ‘Healthcare Investment Show’ in partnership with Discovery Park in London tomorrow (December 5th 2023).

Mayer Schreiber, Chair of Discovery Park Ventures and CEO of Discovery Park, commented: “Our portfolio of investments is making strong progress, and we are delighted by the support our investors have shown us with this second tranche of funding. It is the first step in Discovery Park Ventures’ planned expansion, and we look forward to working with regional investment groups and other funds as we grow.”

DPV has plans to further expand the fund up to £25m in the next three years with a focus on companies developing novel and disruptive technologies that have strong collaborative relationships with Discovery Park.

Contact us